What Researchers Did
Researchers treated a young woman with chemotherapy-resistant rhabdomyosarcoma using an unconventional approach involving radiotherapy, bevacizumab, and statins, followed by surgery and maintenance therapy.
What They Found
The patient's tumor responded clearly to the combined treatment, leading to a radical R0 resection. However, the treatment caused severe side effects including grade IV mucositis, impaired healing of the jaw, and prominent cystitis, which subsided after hyperbaric oxygen therapy.
What This Means for Canadian Patients
For Canadian patients with rhabdomyosarcoma that doesn't respond to standard chemotherapy, this case suggests that a combination of radiotherapy, bevacizumab, and statins might be a viable option. Furthermore, if severe treatment-related side effects occur, hyperbaric oxygen therapy could offer significant relief and aid recovery.
Canadian Relevance
While this study is not Canadian, it demonstrates the use of hyperbaric oxygen therapy to manage severe treatment side effects like impaired healing and cystitis, which fall under Health Canada-recognized indications for HBOT, such as radiation tissue damage and problem wounds.
Study Limitations
As a single case report, this study's findings are not generalizable, and the specific contribution of each adjunct therapy remains unclear.